← Human Trials & Peer-Reviewed Studies
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease
Plain-language guide to PMID 26844873 (2016): single-blind randomized controlled trial study of Octreotide in 27 patients.
Key Facts
- PMID
- 26844873
- Journal
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Pisani A et al. (12 authors)
- DOI
- 10.1016/j.cgh.2015.12.049
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide in this randomized controlled trial publication.
The researchers evaluated the long-term effects of long-acting release octreotide (octreotide LAR), a somatostatin inhibitor, vs placebo in these patients.
Who Took Part
The abstract describes 27 patients taking part.
The age groups tagged for this paper are adults, both men and women.
The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
How the Study Was Run
The researchers set it up as a randomized, single-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.
Only one side, usually the patients, was kept unaware of whether Octreotide was given.
A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.
A time span of 3 years appears in the methods.
What Was Measured
PubMed files the paper under topics including Cysts, Gastrointestinal Agents, Italy, Liver, Liver Diseases, Magnetic Resonance Imaging and Octreotide.
The authors tagged it with the keywords ADPKD Volume, Cyst Growth and Somatostatin Analogue.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Octreotide in 27 patients over 3 years.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association), a journal based in United States.
More context: the Octreotide compound page, all human trials.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.